# PFIZER INC

> Cross-vertical US regulatory timeline. Last 180 days. 95 events.

**Ticker:** PFE · **SEC CIK:** 0000078003

## Vertical activity

| Vertical | Event count |
|---|---:|
| clinical | 66 |
| sec | 18 |
| court | 8 |
| fda | 3 |

## Timeline (newest first)

- **2026-11-19** `clinical.trial` — Pfizer — [Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With Tafamidis](https://api.morvs.ai/clinical/NCT07947940) [importance=25]
- **2026-11-12** `clinical.trial` — Pfizer — [The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and](https://api.morvs.ai/clinical/NCT07932925) [importance=60]
- **2026-11-12** `sec.filing` — 13F-HR — PFIZER INC — 2026-11-12 [importance=30]
- **2026-11-12** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment](https://api.morvs.ai/clinical/NCT07933848) [importance=30]
- **2026-11-12** `clinical.trial` — Pfizer — [A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.](https://api.morvs.ai/clinical/NCT07933835) [importance=30]
- **2026-11-09** `clinical.trial` — Pfizer — [A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B With](https://api.morvs.ai/clinical/NCT07923981) [importance=60]
- **2026-11-09** `clinical.trial` — Pfizer — [A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma](https://api.morvs.ai/clinical/NCT07927023) [importance=25]
- **2026-11-05** `clinical.trial` — Pfizer — [A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA ](https://api.morvs.ai/clinical/NCT07919678) [importance=60]
- **2026-11-04** `clinical.trial` — Pfizer — [A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With ](https://api.morvs.ai/clinical/NCT07915609) [importance=60]
- **2026-11-03** `sec.filing` — 10-Q — PFIZER INC — 2026-11-03 [importance=45]
- **2026-11-03** `sec.filing` — 8-K — PFIZER INC — 2026-11-03 [importance=35]
- **2026-11-03** `sec.filing` — 8-K — PFIZER INC — 2026-11-03 [importance=35]
- **2026-11-02** `clinical.trial` — Pfizer — [Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type ](https://api.morvs.ai/clinical/NCT07909122) [importance=25]
- **2026-10-30** `clinical.trial` — Pfizer — [Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis S](https://api.morvs.ai/clinical/NCT07906262) [importance=25]
- **2026-10-29** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.](https://api.morvs.ai/clinical/NCT07903415) [importance=30]
- **2026-10-28** `clinical.trial` — Pfizer — [A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026](https://api.morvs.ai/clinical/NCT07900139) [importance=25]
- **2026-10-27** `clinical.trial` — Pfizer — [A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Hea](https://api.morvs.ai/clinical/NCT07897708) [importance=30]
- **2026-10-27** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid ](https://api.morvs.ai/clinical/NCT07897721) [importance=30]
- **2026-10-27** `clinical.trial` — Pfizer — [A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients ](https://api.morvs.ai/clinical/NCT07897669) [importance=25]
- **2026-10-22** `clinical.trial` — Pfizer — [A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-](https://api.morvs.ai/clinical/NCT07890597) [importance=60]
- **2026-10-21** `clinical.trial` — Pfizer — [A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults](https://api.morvs.ai/clinical/NCT07885956) [importance=60]
- **2026-10-21** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Oth](https://api.morvs.ai/clinical/NCT07887867) [importance=25]
- **2026-10-19** `clinical.trial` — Pfizer — [A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sl](https://api.morvs.ai/clinical/NCT07881757) [importance=60]
- **2026-10-19** `clinical.trial` — Pfizer — [A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Respon](https://api.morvs.ai/clinical/NCT07881835) [importance=25]
- **2026-10-15** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults Wi](https://api.morvs.ai/clinical/NCT07874633) [importance=60]
- **2026-10-15** `clinical.trial` — Pfizer — [A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Ove](https://api.morvs.ai/clinical/NCT07876518) [importance=30]
- **2026-10-15** `clinical.trial` — Pfizer — [A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With](https://api.morvs.ai/clinical/NCT07876531) [importance=30]
- **2026-10-09** `clinical.trial` — Pfizer — [A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults](https://api.morvs.ai/clinical/NCT07819097) [importance=60]
- **2026-10-09** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma](https://api.morvs.ai/clinical/NCT07869043) [importance=60]
- **2026-10-08** `clinical.trial` — Pfizer — [A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sl](https://api.morvs.ai/clinical/NCT07823608) [importance=60]
- **2026-10-06** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma](https://api.morvs.ai/clinical/NCT07772921) [importance=60]
- **2026-10-06** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema](https://api.morvs.ai/clinical/NCT07783425) [importance=60]
- **2026-10-06** `clinical.trial` — Pfizer — [A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Cas](https://api.morvs.ai/clinical/NCT07779590) [importance=25]
- **2026-10-05** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B](https://api.morvs.ai/clinical/NCT07859527) [importance=25]
- **2026-10-01** `clinical.trial` — Pfizer — [A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases](https://api.morvs.ai/clinical/NCT07782450) [importance=45]
- **2026-10-01** `clinical.trial` — Pfizer — [A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adu](https://api.morvs.ai/clinical/NCT07597928) [importance=30]
- **2026-09-29** `fda.recall` — Pfizer — [Class II](https://api.morvs.ai/recall/D-0052-2027) [importance=60]
- **2026-09-29** `fda.recall` — Pfizer — [Class II](https://api.morvs.ai/recall/D-0051-2027) [importance=60]
- **2026-09-29** `clinical.trial` — Pfizer — [A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off i](https://api.morvs.ai/clinical/NCT07845500) [importance=60]
- **2026-09-29** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obes](https://api.morvs.ai/clinical/NCT07845513) [importance=30]
- **2026-09-28** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity](https://api.morvs.ai/clinical/NCT07595549) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine](https://api.morvs.ai/clinical/NCT07729462) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults](https://api.morvs.ai/clinical/NCT07768345) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults Wit](https://api.morvs.ai/clinical/NCT07792954) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in ](https://api.morvs.ai/clinical/NCT07794774) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in J](https://api.morvs.ai/clinical/NCT07794761) [importance=60]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weig](https://api.morvs.ai/clinical/NCT07663630) [importance=30]
- **2026-09-25** `clinical.trial` — Pfizer — [A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine](https://api.morvs.ai/clinical/NCT07609914) [importance=25]
- **2026-09-24** `clinical.trial` — Pfizer — [A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF](https://api.morvs.ai/clinical/NCT07653100) [importance=60]
- **2026-09-24** `clinical.trial` — Pfizer — [Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease](https://api.morvs.ai/clinical/NCT07839871) [importance=60]

## Provenance

This timeline merges events from these primary sources:

- **SEC EDGAR** — https://www.sec.gov/edgar (filings, insider transactions, Form 144, Schedule 13D/G)
- **openFDA** — https://api.fda.gov/ (recalls, drug labels)
- **USAspending** — https://api.usaspending.gov/ (federal contracts)
- **CourtListener** — https://www.courtlistener.com/ (federal court dockets)
- **CFPB** — https://www.consumerfinance.gov/data-research/consumer-complaints/ (consumer complaints)
- **NIH RePORTER** — https://api.reporter.nih.gov/ (grants)
- **Federal Reserve** — https://www.federalreserve.gov/supervisionreg/enforcementactions.htm (banking enforcement)
- **NHTSA** — https://api.nhtsa.gov/ (vehicle recalls)
- **DOJ** — https://www.justice.gov/news (press releases)
- **EPA ECHO** — https://echo.epa.gov/ (regulated facilities)
- **ClinicalTrials.gov** — https://clinicaltrials.gov/ (drug trials)
- **Senate LDA** — https://lda.senate.gov/ (lobbying disclosures)
- **OFAC** — https://sanctionslistservice.ofac.treas.gov/ (sanctions)

## Citation

> MORVS. Cross-vertical regulatory timeline for PFIZER INC. Retrieved 2026-11-22T19:11:55.432Z from https://api.morvs.ai/entity/PFE. Source terms: https://api.morvs.ai/license.

## Related

- [JSON timeline](https://api.morvs.ai/api/v1/entity/PFE/timeline?days=180)
- [Material events only](https://api.morvs.ai/api/v1/entity/PFE/material-events?days=180)
- [Compliance screen](https://api.morvs.ai/api/v1/screening/all?name=PFIZER%20INC)
- [All cross-vertical entities](https://api.morvs.ai/entity/)
- [Dataset catalog](https://api.morvs.ai/datasets/)

---

*MORVS · [Source-specific license and terms](https://api.morvs.ai/license) · Free or keyless access does not alter source terms.*
